BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

912 related articles for article (PubMed ID: 22748702)

  • 1. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
    Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
    Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
    Papp K; Reich K; Leonardi CL; Kircik L; Chimenti S; Langley RG; Hu C; Stevens RM; Day RM; Gordon KB; Korman NJ; Griffiths CE
    J Am Acad Dermatol; 2015 Jul; 73(1):37-49. PubMed ID: 26089047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
    Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
    Schett G; Wollenhaupt J; Papp K; Joos R; Rodrigues JF; Vessey AR; Hu C; Stevens R; de Vlam KL
    Arthritis Rheum; 2012 Oct; 64(10):3156-67. PubMed ID: 22806399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
    Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
    J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Warren RB; Mrowietz U; von Kiedrowski R; Niesmann J; Wilsmann-Theis D; Ghoreschi K; Zschocke I; Falk TM; Blödorn-Schlicht N; Reich K
    Lancet; 2017 Feb; 389(10068):528-537. PubMed ID: 28012564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
    J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.